Quick Answer
Cardio Diagnostics Holdings, Inc. reported Research And Development Expense of $641.2 thousand for the year ending 2025.
- Cardio Diagnostics Holdings, Inc. showed an increase of +181.3% in Research And Development Expense from 2024 to 2025.
- This data is from Cardio Diagnostics Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on March 13, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2022: $1.1 thousand | Q2 2022: $5.0 thousand | Q3 2022: $3.2 thousand | Q1 2023: $86.7 thousand | Q2 2023: $12.3 thousand | Q3 2023: $38.7 thousand | Q1 2024: $10.8 thousand | Q2 2024: $7.3 thousand | Q3 2024: $5.2 thousand | Q1 2025: $2.2 thousand.
- Over the full 5 years of available data (2021 to 2025), Cardio Diagnostics Holdings, Inc.'s Research And Development Expense has grown by 1,937.7%.
- Historical annual values: Fiscal year 2025: $641.2 thousand | Fiscal year 2024: $228.0 thousand | Fiscal year 2023: $145.2 thousand | Fiscal year 2022: $40.4 thousand | Fiscal year 2021: $31.5 thousand.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: